Prostate cancer
Conditions
Interventions
67.5GyE in 25 fractions with a fractional dose of 2.7Gy
Sponsors
Aizawa hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Pathologically proven adenocarcinoma of the prostate 2) cT1c-T4N0M0(UICC 7th) Prostate cancer 3) ECOG-PS 0-2 4) Age 20-yrs old or over at the time of consent form is obtained 5) Well informed and documented consent from the patient
Exclusion criteria
Exclusion criteria: 1) With active other cancers 2) With severe uncontrolled diabetes 3) With severe heart disease, or some serious complications, i.e., SLE, Scleroderma, interstitial pneumonia 4) Allergic to radiation 5) Previous surgical treatment for prostate disease before enrollment 6) Previous chemotherapy (except holmonal therapy)for prostate cancer before enrollment 7) Previous radiotherapy to pelvis 8) With implantable cardioverter defibrillator or permanent pacemaker 9) Considered that participation in this trial is difficult because of psychiatric symptoms or psychosis 10) Cannot be held rest for about 60 minutes 11) Cannot be implanted Au marker in the prostate 12) Unsuitable for enrollment judged by principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 5-year rate of Grade 2 or worse late toxicity | — |
Secondary
| Measure | Time frame |
|---|---|
| Acute and late toxicity rate, biochemical relapse-free rate, overall survival rate, cause-specific survival rate, and clinical relapse-free survival rate at 5 years | — |
Countries
Japan
Contacts
Public ContactMasayuki Araya
Aizawa hospital Proton therapy center
Outcome results
None listed